Table 2

Demographics of patients in our cohort, stratified by cardiac event

No cardiac event in 100 daysCardiac event in 100 daysTotal*P value
n29283013229
Age64.2 (10.7)65.6 (11.3)64.4 (10.8)0.066
RaceWhite1996 (68.2)227 (75.4)2223 (68.8)0.004
Black or African–American410 (14.0)45 (15.0)455 (14.1)
Other race446 (15.2)23 (7.6)469 (14.5)
Missing76 (2.6)6 (2.0)82 (2.5)
EthnicityHispanic or Latino76 (2.6)6 (2.0)82 (2.5)0.244
Not Hispanic or latino2275 (77.7)224 (74.4)2499 (77.4)
Unknown577 (19.7)71 (23.6)648 (20.1)
SexFemale1379 (47.1)118 (39.2)1497 (46.4)0.031
Male1548 (52.9)183 (60.8)1731 (53.6)
Unknown1 (0.0)1 (0.0)
Cancer typeLung2355 (80.4)266 (88.4)2621 (81.2)0.004
Melanoma365 (12.5)23 (7.6)388 (12.0)
RCC208 (7.1)12 (4.0)220 (6.8)
Stage at indexMissing143 (4.9)21 (7.0)164 (5.1)0.028
Stage 02 (0.1)2 (0.1)
Stage 192 (3.1)5 (1.7)97 (3.0)
Stage 2118 (4.0)7 (2.3)125 (3.9)
Stage 3480 (16.4)34 (11.3)514 (15.9)
Stage 42093 (71.5)234 (77.7)2327 (72.1)
Stage at DiagnosisMissing154 (5.3)25 (8.3)179 (5.5)0.050
Stage 1207 (7.1)13 (4.3)220 (6.8)
Stage 2214 (7.3)20 (6.6)234 (7.2)
Stage 3675 (23.1)60 (19.9)735 (22.8)
Stage 41678 (57.3)183 (60.8)1861 (57.6)
Smoking statusEx-smoker1111 (37.9)125 (41.5)1236 (38.3)0.024
Missing/unknown447 (15.3)31 (10.3)478 (14.8)
Never smoker397 (13.6)31 (10.3)428 (13.3)
Smoker973 (33.2)114 (37.9)1087 (33.7)
ECOG score0574 (19.6)49 (16.3)623 (19.3)0.006
11040 (35.5)110 (36.5)1150 (35.6)
2311 (10.6)41 (13.6)352 (10.9)
351 (1.7)13 (4.3)64 (2.0)
42 (0.1)1 (0.3)3 (0.1)
Missing950 (32.4)87 (28.9)1037 (32.1)
Charlson score04 (0.1)2 (0.7)6 (0.2)0.004
1–2436 (14.9)28 (9.3)464 (14.4)
3+2488 (85.0)271 (90.0)2759 (85.4)
AIDS–HIV9 (0.3)1 (0.3)10 (0.3)1.000
Cerebrovascular disease84 (2.9)13 (4.3)97 (3.0)0.220
Chronic pulmonary disease907 (31.0)122 (40.5)1029 (31.9)0.001
Congestive heart failure265 (9.1)35 (11.6)300 (9.3)0.173
Dementia9 (0.3)2 (0.7)11 (0.3)0.274
Diabetes mellitus with chronic complication44 (1.5)2 (0.7)46 (1.4)0.314
Diabetes mellitus without chronic complication434 (14.8)51 (16.9)485 (15.0)0.370
Hemiplegia or paraplegia8 (0.3)8 (0.2)1.000
Malignancy2924 (99.9)299 (99.3)3223 (99.8)0.101
Metastatic solid tumor2128 (72.7)228 (75.7)2356 (73.0)0.283
Mild liver disease133 (4.5)17 (5.6)150 (4.6)0.469
Moderate or severe liver disease7 (0.2)7 (0.2)1.000
Myocardial infarction132 (4.5)17 (5.6)149 (4.6)0.451
Peptic ulcer disease27 (0.9)3 (1.0)30 (0.9)0.755
Peripheral vascular disease118 (4.0)17 (5.6)135 (4.2)0.236
Renal disease179 (6.1)24 (8.0)203 (6.3)0.254
Rheumatic disease38 (1.3)6 (2.0)44 (1.4)0.296
PD-1/PD-L1 therapyAtezolizumab171 (5.8)12 (4.0)183 (5.7)0.233
Avelumab3 (0.1)3 (0.1)
Durvalumab65 (2.2)2 (0.7)67 (2.1)
Nivolumab1921 (65.6)207 (68.8)2128 (65.9)
Pembrolizumab768 (26.2)80 (26.6)848 (26.3)
PD-1 testingMissing2331 (79.6)235 (78.1)2566 (79.5)0.497
Negative143 (4.9)11 (3.7)154 (4.8)
Not interpretable133 (4.5)15 (5.0)148 (4.6)
Positive321 (11.0)40 (13.3)361 (11.2)
  • *Excludes patients censored in first 100 days.

  • †Mean (SD).

  • ECOG, Eastern Cooperative Oncology Group; PD-1, programmed death receptor-1.